Impact of angionesis in gynecology and obstetrics;Angiogenese in gynakologie und geburtshilfe

Wiener Klinische Wochenschrift

Volumn 111, Issue 7, 1999, Pages 262-277

  Obermair, Andreas ^b   Preyer, Oliver ^c   Leodolter, Sepp ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c NONE

Author keywords

Angiogenesis; Gynecology; Neovascularisation; Obstetrics

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 8; LEFLUNOMIDE; MARIMASTAT; OCTREOTIDE; PENTOSAN POLYSULFATE; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; ROQUINIMEX; SCATTER FACTOR; SURAMIN; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENIC FACTOR; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN A;

ANGIOGENESIS; CELL DENSITY; ENDOMETRIOSIS; FEMALE; GROWTH INHIBITION; GYNECOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MENSTRUAL CYCLE; OBSTETRICS; PREECLAMPSIA; PROGNOSIS; REVIEW; TUMOR GROWTH; FEMALE GENITAL SYSTEM; FEMALE GENITAL TRACT TUMOR; MICROCIRCULATION; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITALIA, FEMALE; HUMANS; INFANT, NEWBORN; LYMPHOKINES; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033537736     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Jaffe EA (1987) Cell biology of endothelial cells. Hum Pathol 18: 234-239
2. Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196
3. Hobson B, Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49: 405-413
4. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31
5. McLaren J, Prentice A, Charnock-Jones DS, Smith SK (1996) Vascular endothelial growth factor concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11: 220-223
6. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, Smith SK (1996) Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 98: 482-489
7. Wiczyk HP, Grow DR, Adams LA, O'Shea DL, Reece MT (1998) Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors. Fertil Steril 69: 511-516
8. Folkman J (1971)Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
9. Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164: 491-502
10. Folkman J, Winsey S, Cole P, Hodes R (1968) Isolated perfusion of thymus. Exp Cell Res 53: 205-214
11. Gimbrone MA Jr, Aster RH, Cotran RS, Corkery J, Jandl JH, Folkman J (1969) Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 221: 33-36
12. Folkman J, Klagsburn M (1987) Angiogenic factors. Science 235: 442-447
13. Greenblatt M, Shubik P (1968) Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41: 111-124
14. Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52: 413-427
15. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276
16. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15: 177-186
17. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, et al (1991) Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180-6184
18. Ferrara N (1996) Vascular endothelial growth factor. Eur J Cancer 32A: 2413-2422
19. Melnyk O, Shuman MA, Kim KJ (1996) Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921-924
20. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579
21. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149-153
22. Koike A, Moore GE, Mendoza CB, Watne AL (1963) Heterologous, homologous, and autologous transplantation of human tumors. Cancer 16: 1065-1071
23. Clark WH Jr., Elder DE, Guerry DIV, Braitman LE, Track BJ, Schultz D, Synnestevdt M, Halpern AC (1989) Model predicing survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81: 1893-1904
24. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
25. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704
26. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistence. Nature 390: 404-407
27. Gimbrone MA Jr, Gullino PM (1976) Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 56: 305-318
28. Brem SS, Gullino PM, Medina D (1977) Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195: 880-882
29. Smith-McCune KK, Weidner N (1994) Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804
30. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, et al (1995) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237-1245
31. Abulafia O, Triest WE, Sherer DM (1996) Angiogenesis in squamous cell carcinoma in situ and microinvasive carcinoma of the uterine cervix. Obstet Gynecol 88: 927-932
32. Soini Y, Pollanen R, Kemppainen S, Paakko P, Lehto VP (1996) The association of vascular proliferation with HPV status and epithelial PCNA positivity in cervical intraepithelial lesions. APMIS 104: 183-190
33. Obermair A, Bancher-Todesca D, Bilgi S, Kaider A, Kohlberger P, Mullauer-Ertl S, et al (1997) Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 89: 1212-1217
34. Dobbs SP, Hewett PW, Johnson IR, Carmichael J, Murray JC (1997) Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 76: 1410-1415
35. Davidson B, Goldberg I, Kopolovic J (1997) Angiogenesis in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study. Int J Gynecol Pathol 16: 335-338
36. Bancher-Todesca D, Obermair A, Bilgi S, Kohlberger P, Kainz C, Breitenecker G, et al (1997) Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 64: 496-500
37. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F (1995) Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 86: 479-485
38. Brem SS, Jensen HM, Gullino PM (1978) Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41: 239-244
39. Jensen HM, Chen I, DeVault MR, Lewis AE (1982) Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 218: 293-295
40. Guidi AJ, Fischer L, Harris JR, Schnitt SJ (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86: 614-619
41. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8
42. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33-41
43. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, et al (1996) Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69: 205-211
44. Abulafia O, Triest WE, Sherer DM (1997) Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 177: 541-547
45. Schoell WM, Pieber D, Reich O, Lahousen M, Janicek M, Guecer F, et al (1997) Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer 80: 2257-2262
46. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106
47. Obermair A, Wasicky R, Kaider A, Preyer O, Leodolter S, Lösch A, et al (1998) Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. (Data submitted)
48. Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, et al (1996) Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 174: 1879-1882; discussion 1882-1884
49. Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, et al (1997) Angiogenesis in endometrial carcinoma. Cancer 80: 741-747
50. Salvesen HB, Iversen OE, Akslen LA (1998) Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 77: 1140-1144
51. Wagatsuma S, Konno R, Sato S, Yajima A (1998) Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 82: 520-530
52. Obermair A, Tempfer C, Wasicky R, Kaider A, Hefler L, Kainz C (1998) Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol (In press)
53. Wiggins DL, Granai CO, Steinhoff MM, Calabresi P (1995) Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56: 353-356
54. Kainz C, Speiser P, Wanner C, Obermair A, Tempfer C, Sliutz G, et al (1995) Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res 15: 1549-1551
55. Schlenger K, Hockel M, Mitze M, Schaffer U, Weikel W, Knapstein PG, et al (1995) Tumor vascularity-a novel prognostic factor in advanced cervical carcinoma. Gynecol Oncol 59: 57-66
56. Rutgers JL, Mattox TF, Vargas MP (1995) Angiogenesis in uterine cervical squamous cell carcinoma. Int J Gynecol Pathol 14: 114-118
57. Dinh TV, Hannigan EV, Smith ER, Hove MJ, Chopra V, To T (1996) Tumor angiogenesis as a predictor of recurrence in stage Ib squamous cell carcinoma of the cervix. Obstet Gynecol 87: 751-754
58. Bremer GL, Tiebosch AT, van-der-Putten HW, Schouten HJ, de-Haan J, Arends JW (1996) Tumor angiogenesis: an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol 174: 126-131
59. Avall-Lundqvist EH, Silfversward C, Aspenblad U, Nilsson BR, Auer GU (1997) The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 33: 1799-1804
60. Dellas A, Moch H, Schultheiss E, Feichter G, Almendral AC, Gudat-F, et al (1997) Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol Oncol 67: 27-33
61. Obermair A, Wanner C, Bilgi S, Speiser P, Kaider A, Reinthaller A, et al (1998) Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am J Obstet Gynecol 178: 314-319
62. Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, et al (1996) Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 63: 204-209
63. McCulloch P, Choy A, Martin L (1995) Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346: 1334-1335
64. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, et al (1997) Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89: 1044-1049
65. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla-Palma P (1995) Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma-results of a multiparametric study. Breast Cancer Res Treat 36: 205-217
66. Hall NR, Fish DE, Hunt N, Goldin RD, Guillou PJ, Monson JR (1992) Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1: 223-229
67. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, et al (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124
68. Obermair A, Czerwenka K, Kurz C, Kaider A, Sevelda P (1994) Tumoral vascular density in breast tumors and their effect on recurrence-free survival. Chirurg 65: 611-615
69. Toi M, Kashitani J, Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55: 371-374
70. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM (1993) Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A: 1141-1145
71. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL (1994) Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109-116
72. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, et al (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466
73. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S (1996) Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88: 1764-1769
74. Obermair A, Kurz C, Czerwenka K, Thoma M, Kaider A, Wagner T, et al (1995) Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 62: 126-131
75. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887
76. Axelsson K, Ljung BM, Moore DH 2nd, Thor AD, Chew KL, Edgerton SM, et al (1995) Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87: 997-1008
77. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180
78. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19
79. Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, et al (1997) Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74: 455-458
80. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147
81. Reif M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969
82. Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, et al (1997) Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 75: 28-33
83. Obermair A, Speiser P, Reisenberger K, Ullrich R, Czerwenka K, Kaider A (1998) Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett 130: 1-8
84. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, et al (1997) Vascular endothelial growth factor (VEGF) expression ans survival in human epithelial ovarian carcinomas. Cancer Lett 121: 169-175
85. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T, et al (1991) Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180: 386-392
86. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86: 356-361
87. Sliutz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G, Kainz C (1995) Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 94: 227-231
88. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H (1994) Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221: 211-214
89. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, et al (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185-2190
90. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De-Pooter C, et al (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238-243
91. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227
92. Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zeillinger R, et al (1998) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer 77: 1870-1874
93. Tempfer C, Obermair A, Hefler L, Häusler G, Gitsch G, Kainz C (1998) Vascular endoethelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92: 360-363
94. Huang SC, Yu CH, Huang RT, Hsu KF, Tsai YC, Chou CY (1996) Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 87: 1019-1024]
95. Peters-Engl C, Medl M, Mirau M, Wanner C, Bilgi S, Sevelda P, et al (1998) Color-coded and spectral Doppler flow in breast carcinomas-relationship with the tumor microvasculature. Breast Cancer Res Treat 47: 83-89
96. Meyerowitz CB, Fleischer AC, Pickens DR, Thurman GB, Borowsky AD, Thirsk G, Hellerqvist CG (1996) Quantification of tumor vascularity and flow with amplitude color Doppler sonography in an experimental model: preliminary results. J Ultrasound Med 15: 827-833
97. Auerbach R, Auerbach W, Polakowski I (1991) Assays for angiogenesis: a review. Pharmacol Ther 51: 1-11
98. Jain RK, Schlenger K, Höckel M, Yuan F (1997) Quantitative angiogenesis assays: progress and problems. Nat Med 3: 1203-1208
99. Sandison JC (1924) A new method for the microscopic study of living growing tissues by the introduction of a transparent chamber in the rabitti's ear. Anat Rec 28: 281-287
100. Patan S, Munn LL, Jain RK (1996) Intussceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvase Res 51: 260-272
101. Nguyen M, Shing Y, Folkman J (1994) Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47: 31-40
102. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330
103. Wellstein A, Czubayko F (1996) Inhibition of fibroblast growth factors. Breast Cancer Res Treat 38: 109-119
104. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, et al. (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545
105. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599
106. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93: 4851-4856
107. Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC (1998) Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 41: 117-124
108. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456-1463
109. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour-growth. Nature 348: 555-557
110. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, et al (1997) A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3: 1501-1505
111. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M, Saul A, Estrada-Parra S, et al (1998) IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol 116: 60-66
112. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D (1996) Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 23: 501-503, discussion 504-505
113. Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072
114. McGuire MB, Murphy G, Reynolds JJ, Russell RG (1981) Production of collagenase and inhibitor (TIMP) by normal, rheumatoid and osteoarthrilic synovium in vitro: effects of hydrocortisone and indomethacin. Clin Sci 61: 703-710
115. Afzal S, Lalani-el N, Foulkes WD, Boyce B, Tickle S, Cardillo MR, et al (1996) Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74: 406-421
116. Kikkawa F, Tamakoshi K, Nawa A, Shibata K, Yamagata S, Yamagata T, et al (1997) Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues. Cancer Lett 120: 109-115
117. Malfetano J, Teng N, Moore D, Barter J, Lopez A, Schink J et al (1996) Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: a dose-finding study. Proc Am Soc Clin Oncol 15: 283
118. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
119. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
120. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502
121. Benoy I, Vermeulen P, Wuyts H, Dirix L (1998) Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle. Eur J Cancer 34: 1298-1299
122. Ferrara N, Chen H, Davis-Smith T, Gerber HP, Nguyen TN (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340
123. Obermair A, Obruca A, Kaider A, Pöhl M, Vales A, Leodolter S, et al (1998) Vascular endothelial growth factor and its receptors in male fertility. (Data submitted)
124. Hertig AT (1935) Angiogenesis in the early human chorion and in the primary placenta of the macaque monkey. Contributions to Embryology 146: 39-81
125. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS (1996) Localization of VEGF and expression of its receptors fit and KDR in human placenta throughout pregnancy. Hum Reprod 11: 1090-1098
126. Anthony FW, Evans PW, Wheeler T, Wood PJ (1997) Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 34: 276-280
127. Evans P, Wheeler T, Anthony F, Osmond C (1997) Maternal serum vascular endothelial growth factor during early pregnancy. Clin Sci Colch 92: 567-571
128. Baker PN, Krasnow J, Roberts JM, Yeo KT (1995) Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 86: 815-821
129. Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, Charnock-Jones DS et al (1996) Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by preeclampsia. Eur J Clin Invest 26: 1182-1185
130. Lyall F, Greer IA, Boswell F, Fleming R (1997) Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 104: 223-228
131. Lyall F, Young A, Boswell F, Kingdom JC, Greer IA (1997) Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 18: 269-276